Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Iclusig

Iclusig 15 mg film-coated tablets Iclusig 30 mg film-coated tablets Iclusig 45 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 23

HOS-128532 · Präparat HOS-096579

Table 10 Adverse Reactions observed in newly diagnosed Ph+ ALL patients in PhALLCON Study – frequency reported by incidence of treatment emergent events Ponatinib in combination with reduced- System Organ Class Frequency intensity chemotherapy Adverse reactions Pneumonia Conjunctivitis Infections and infestations Common Sepsis Septic shock Neutropenic infection Thrombocytopenia Anemia Neutropenia Very common Febrile neutropenia Blood and lymphatic system Leukopenia disorders Leukocytosis Myelosuppression Lymphopenia Common Cytopenia Agranulocytosis Hypokalaemia Hyperglycaemia Very common Hypocalcaemia Hypophosphataemia Hyperuricaemia Metabolism and nutrition Decreased appetite disorders Hypertriglyceridaemia Hyponatraemia Common Hypoalbuminaemia Hypercholesterolaemia Dyslipidaemia Fluid retention Psychiatric disorders Very common Insomnia Headache Neuropathy peripheral Very common Paraesthesia Nervous system disorders Peripheral sensory neuropathy Dizziness Common Hypoaesthesia

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.